StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Evofem Biosciences's profit margin for the twelve months ending Jun 30, 2026 was -84.7%. For fiscal 2025 it was 1.9%, against -45.8% the year before. The highest annual figure on record is 290.8% in fiscal 2023.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20251.9%+47.7
FY2024Dec 31, 2024-45.8%−336.6
FY2023Dec 31, 2023290.8%+746.3
FY2022Dec 31, 2022-455.5%+2033.5
FY2021Dec 31, 2021-2489.0%+29418.9
FY2020Dec 31, 2020-31907.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-419.1%−382.2
Q1 FY2026Mar 31, 2026-607.9%−721.0
Q4 FY2025Dec 31, 202529.2%+71.9
Q3 FY2025Sep 30, 2025-31.7%+20.9
Q2 FY2025Jun 30, 2025-37.0%−69.5
Q1 FY2025Mar 31, 2025113.1%+246.6
Q4 FY2024Dec 31, 2024-42.8%+305.4
Q3 FY2024Sep 30, 2024-52.6%−12.1
Q2 FY2024Jun 30, 202432.5%+4638.0
Q1 FY2024Mar 31, 2024-133.5%−1538.4
Q2 FY2023Jun 30, 2023-348.2%+1739.7
Q1 FY2023Mar 31, 2023-40.5%+709.6
Q4 FY2022Dec 31, 2022-4605.5%−3161.4
Q3 FY2022Sep 30, 20221404.9%+5730.9
Q2 FY2022Jun 30, 2022-2087.8%−287.8
Q1 FY2022Mar 31, 2022-750.1%+3426.4
Q4 FY2021Dec 31, 2021-1444.1%+22721.4
Q3 FY2021Sep 30, 2021-4326.0%+6429.0
Q2 FY2021Jun 30, 2021-1800.0%–
Q1 FY2021Mar 31, 2021-4176.6%–
Q4 FY2020Dec 31, 2020-24165.5%–
Q3 FY2020Sep 30, 2020-10755.0%–

More Evofem Biosciences figures

See a number that looks wrong?